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Editor’s key points
† Propofol induced matrix
metalloproteinase
activity in rat cardiac
fibroblasts under
conditions of hypoxia–
reoxygenation.
† Cell migration, invasion,
and proliferation were
increased by propofol.
† This may explain the
cardioprotective effects
of propofol after
ischaemia–reperfusion.
Background. Propofol is known to protect the myocardium against ischaemia/reperfusion
(I/R) injury through its antioxidant and anti-inflammatory properties. Matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are
involved in cell migration and invasion, and mediate tissue remodelling during I/R injury.
They are regulated by various mechanisms including oxidative stress and AKT and ERK
pathways. We investigated whether propofol affected the expression of MMPs and
subsequent cell migration and invasion and the signalling pathways involved in primary
rat cardiac fibroblasts undergoing hypoxia and reoxygenation.
Methods. The phosphorylation of ERK and AKT signalling pathways was examined by
western blot analysis in rat primary cardiac fibroblasts after hypoxia and reoxygenation.
mRNA expression of MMP and TIMPS was analysed by real-time PCR, and proteolytic
activities of MMP-2 and -9 were assessed. The effects of propofol on migration, invasion,
wound healing, and cell proliferation activity were evaluated after reoxygenation.
Results. Propofol induced AKT and ERK1/2 activation. Subsequent activation of MMPs
resulted in increased cell migration, invasion, and wound-healing activity under hypoxia–
reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK
inhibitor) in rat cardiac fibroblasts. However, propofol had no effect on proliferation or
viability of cardiac fibroblasts after hypoxia–reoxygenation.
Conclusions. Propofol affected the expression of MMPs and TIMPs and subsequently induced
cell migration and invasive ability, through activation of the ERK and AKT signalling pathway
in hypoxia-reoxygenated rat cardiac fibroblasts.
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Matrix metalloproteinases (MMPs) are members of the zinc-
dependent endopeptidase family that play an important
role in the development, morphogenesis, angiogenesis, and
turnover of the extracellular matrix (ECM).1 2 Tissue inhibitors
of metalloproteinases (TIMPs) inhibit the proteinase activities
of MMPs,3 and the balance between the MMPs and TIMPs
controls local activities of MMPs in tissues.2 4
MMPs are important stimulators of cardiac fibroblasts, the
most abundant cell type in the normal heart, playing a key
role in cardiac remodelling and fibrosis after ischaemia/
reperfusion (I/R) injury.5 6 Accordingly, the pathological
activities of the MMPs, TIMPs, and membrane-type
(MT)-MMPs are closely associated with vascular remodelling,
fibrosis, and left ventricular remodelling after I/R injury.7 8
Diverse signalling pathways including mitogen-activated
protein kinases (MAPKs), extracellular signalling-regulated
kinase,9 and AKT are responsible for the regulation of MMPs,
TIMPs, and MT-MMPs.1 10 In addition, phosphatidylinositol 3-
kinase (PI3K)/AKTand MAPKs signalling pathways were demon-
strated to be involved in cardiac disease or cardioprotective
processes through regulation of expression of MMPs.11 – 13
Propofol (2,6-di-isopropylphenol), an i.v. anaesthetic
agent, has free radical scavenging properties,14 providing
both vascular and cardioprotective effects against I/R
injury.15 Post-conditioning with propofol was shown to miti-
gate ischaemic brain injury through activation of the PI3K/
AKT pathway16 and propofol-induced ERK activation was pro-
tective in neuronal cells.17 In the heart, propofol inhibited
angiotensin II-mediated cardiomyocyte hypertrophy and
promoted myocardial angiogenesis.18
Despite the theoretical background that propofol could
modulate the activities of AKT and ERK pathways and
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protect against I/R-induced injury, there are no data regard-
ing the effects of propofol on expression of MMPs and sub-
sequent changes in cardiac fibroblast activities in I/R injury.
This study investigated whether propofol influences MMPs
and TIMPs expression and the role of AKT and ERK and sub-
sequent proliferation, migration, and invasion activities of rat
cardiac fibroblasts under conditions of hypoxia–
reoxygenation.
Methods
Primary culture of rat cardiac fibroblasts
The animal procedures were approved by the committee for
the Care and Use of Laboratory Animals, Yonsei University
College of Medicine, and were performed in accordance
with the Committee’s Guidelines and Regulations for
Animal Care. Isolated neonatal cardiac fibroblasts were
obtained as described previously.19 In brief, 1- to 2-day-old
Sprague–Dawley neonatal rat pups were killed and the
hearts were dissected under sterile conditions. Minced ventri-
cular myocardium was digested consecutively for 10, 6×10
min each, using an enzyme mixture containing 1% (w/v)
trypsin, 0.5 mM EDTA, and 0.1% collagenase in HEPES. The
dissociated cells were mixed with alpha-minimum essential
medium (a-MEM) containing 5.5 mM glucose, supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin solution and were centrifuged and pooled. Culture
media and supplements were purchased from Hyclone
(Logan, UT, USA). The resulting dissociated cell mixture
was pre-plated for 1 h in a 5% CO2-containing incubator
at 378C for isolation of fibroblasts. After removal of the
myocyte-enriched medium, culture medium was then
added to the pre-plated fibroblasts and cultured overnight.
Cardiac fibroblasts were used at the second to fourth
passage.
Gelatin zymography
Levels of secreted pro- and active MMP-2 and MMP-9 were
evaluated using gelatin zymography. Fibroblasts were
plated into 6-well culture plates with culture medium, incu-
bated for 24 h, and serum-starved overnight in serum-free
medium supplemented with 1% bovine serum albumin
(BSA). Cells were transferred to fresh medium and incubated
for 8 h in conditions of normoxia (5% CO2 in air) or hypoxia
(1% O2, 5% CO2, 94% N2). Aliquots of conditioned media
were separated by electrophoresis in 10% gelatin zymogram
gels (Invitrogen Life Technologies, Carlsbad, CA, USA) after
which the gels were washed twice in denaturing buffer
(2.5% Triton X-100, 50 mM Tris–Cl, pH 7.5) at room tempera-
ture for 30 min followed by developing buffer (150 mM NaCl,
10 mM CaCl2, 50 mM Tris–Cl, pH 7.5) at room temperature for
30 min, and finally developing buffer at 378C for 16–18
h. These gels were stained with 0.1% Coomassie brilliant
blue in 10% methanol and 10% acetic acid. After destaining,
MMP-9, pro-MMP-2, and active MMP-2 were seen as clear
bands (92, 72, and 62 kDa, respectively).
RNA isolation and real-time PCR
Expression levels of MMPs and TIMPs were examined by real-
time PCR. Total RNA was isolated using RNeasy-mini kits
(Qiagen, Valencia, CA, USA). cDNA was synthesized from 1
mg of total RNA by using Maxime RT PreMix kit (iNtRON
Biotechnology, Sungnam, Korea). Real-time PCR analysis
was performed using SYBR Premix Ex TaqTM (TaKaRa, Otsu,
Japan) and an AB 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Each sample was analysed
in quadruplicate and target genes were normalized to the
reference housekeeping gene, glyceraldehyde-3-phosphate
dehydrogenase. Fold differences were then calculated for
each treatment group using normalized CT values for the
control. Rat genes and their primer sequences for real-time
PCR are given in Supplementary Table S1.
Immunoblot analysis
Fibroblasts were seeded into 60 mm tissue culture dishes,
incubated for 24 h, and serum-starved overnight. Cells were
then transferred to fresh medium and incubated as pre-
viously. The cells were then washed with ice-cold PBS and
lysed in cell lysis buffer (10 mM Tris–Cl, pH 7.5, 150 mM
NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM NaF, 0.2 mM Na3VO4, and
1 mM PMSF) with a supplement of complete protease inhibi-
tor cocktail tablets (Roche Diagnostics, Mannheim, Germany)
and sonicated briefly. Protein concentrations were deter-
mined using the Bradford protein assay with BSA as a stan-
dard (Bio-Rad, Hercules, CA, USA). Samples containing
equal amounts of protein (50 mg) were subjected to
SDS–polyacrylamide gel electrophoresis, after which the
separated proteins were transferred onto a polyvinylidene
difluoride membrane (Millipore, Bedford, MA, USA). The
membrane was blocked with 5% non-fat, dried milk in Tris-
buffered saline containing 0.1% Tween 20 and incubated
with primary antibody followed by a horseradish peroxidase
conjugated secondary antibody. The following primary
antibodies were used: ERK1/2, phospho-ERK1/2, AKT,
phospho-AKT, and Actin (Cell Signaling, Beverly, MA, USA).
The luminescence was detected using WEST-ZOL western
blot detection kit (iNtRON Biotechnology, Sungnam, Korea)
in a LAS4000 (Fuji PhotoFilm, Tokyo, Japan).
Cell migration and invasion assays
Serum-starved fibroblasts were pretreated with U0126 (ERK
inhibitor, 20 mM), or LY294002 (AKT inhibitor, 10 mM) or a
vehicle control for 1 h, followed by propofol (30 mM) or a
vehicle control for 1 h, and further exposed to hypoxia for
1 h in MEM supplemented with 0.1% BSA, 2 mM CaCl2, and
2 mM MgCl2. These cells were trypsinized and seeded into
the inner chamber of a 24-well migration or invasion plate
followed by reoxygenation for 24 h.
Migration and invasion assays were assessed using a
modified Boyden chamber technique with Matrigel basement
membrane matrix-coated membranes pore size 8 mm
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(CytoSelectTM Cell migration and invasion assay kit, Cell
Biolabs, CA, USA). Chemoattractant (10% FBS in MEM) was
loaded into the lower well of the migration or invasion
plate. After the incubation period in hypoxia–reoxygenation
conditions, migration or invasion processing was performed
according to the manufacturer’s instructions. Each exper-
iment was performed at least six times.
Cell proliferation assay
Cardiac fibroblasts were seeded into 96-well culture plates
and incubated for 24 h. After propofol pretreatment for 1 h
at concentrations indicated, cells were exposed to hypoxia
for 1 h followed by reoxygenation for 1–2 days. After each
time of incubation, cell proliferation was assessed by the
Cell counting kit (CCK-8, Dojindo Molecular Technologies,
Kumamoto, Japan) according to the manufacturer’s
instructions.
Statistical analysis
Data are shown as raw data points apart from cell prolifer-
ation assay data which are shown as mean (SEM) and statisti-
cal differences were analysed using Student’s t-test following
the Bonferroni correction. A P-value of ,0.05 was considered
significant.
Results
ERK and AKT signalling pathway in primaries
Propofol induced phosphorylation of AKT and ERK within
0.5–15 and 1–15 min, respectively (Fig. 1A). Propofol treat-
ment for 5 min at about 10–50 mM increased AKT and ERK
phosphorylation in cardiac fibroblasts (Fig. 1B). In this study,
commercially sold propofol solubilized in 10% intralipid
emulsion was used. There was no difference in AKT and
ERK activities between 10% intralipid emulsion and DMSO-
treated cells (data not shown).
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Fig 1 Propofol-induced changes in AKT and ERK signalling for the indicated times (A, upper panel) and at the indicated concentration (B, upper
panel), and quantified signal (A and B, lower panel). Figure shows raw data points.
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mRNA expression of MMP and TIMP
In normoxic condition, expression of MMPs mRNA progress-
ively increased with time and MT1-MMP and TIMP-2 mRNA
expression at 24 h was higher than baseline values. Propofol
increased MMPs and MT1-MMP mRNA expression in the same
pattern but not TIMP-2 mRNA (Fig. 2A–H). MMP-1 and MMP-13
mRNA expression at 6 h, and MMP-8 and -9 mRNA expression
at 12 h were higher in propofol-treated cells than in the
control cells. MMP-2 and -3 mRNA expression at 6 and 12 h
was also higher in the propofol-treated cells. In addition,
MT1-MMP mRNA expression was higher and TIMP-2 mRNA
expression was lower at 12 h in propofol-treated cells. Propo-
fol enhanced the proteolytic activity of MMP-2 and of MMP-9
about 5.8-fold (Fig. 2I).
Inhibition of ERK and AKT signalling pathways
Pretreatment with LY294002 (AKT inhibitor) or U0126 (ERK
inhibitor) for 1 h suppressed propofol-induced MMP-1, -2,
and -9 mRNA expression (Fig. 3A–C). The decrease in
TIMP-2 mRNA expression mediated by propofol was also
attenuated by LY294002 or U0126 (Fig. 3D). Propofol-induced
increased proteolytic activity of MMP-2 was attenuated by
inhibiting AKT and ERK signalling (Fig. 3E and F). LY294002
decreased propofol-induced ERK activation and U0126 also
decreased propofol-induced AKT activation (Fig. 3G), demon-
strating that the propofol regulated MMPs and TIMP-2
expression via AKT and ERK signalling pathways.
mRNA expression of MMPs TIMPs under conditions
of hypoxia–reoxygenation
MMP-1, -9, and -13 mRNA expression was increased by
propofol after hypoxia–reoxygenation compared with that
of control cells (Fig. 4). MMP-2 mRNA expression was less
during hypoxia and for 3 h after reoxygenation in the
propofol-treated cells but was greater at 6 and 12 h after
reoxygenation in the propofol-treated cells. TIMP-1 mRNA
expression 1 h after reoxygenation and TIMP-2 and -3
mRNA expression during hypoxia and early reoxygenation
were higher in the propofol-treated cells than control cells.
However, TIMP-1, -2, and -3 mRNA levels at 24 h after reoxy-
genation decreased by more than 50% in the propofol-
treated cells.
Cell migration, invasion, proliferation, and viability
Cell migration and invasion were enhanced by propofol-
treated cells compared with control cells and were
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attenuated by AKT and ERK inhibitors (Fig. 5A and B). Cell pro-
liferation was not affected by lower concentrations of propo-
fol under hypoxia–reoxygenation conditions, although a
significant decrease in cell proliferation was seen after
exposure to 200 mM propofol for 2 days (Fig. 5C).
Discussion
We showed that propofol regulated mRNA expression of
MMPs and TIMPs through ERK and AKT signalling pathways,
leading to enhanced cell migration and invasive ability
without affecting cell proliferation, in rat cardiac fibroblasts.
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Notwithstanding the restoration of coronary blood flow,
I/R injury triggers stress-signalling processes that eventually
result in pathological damage to the myocardium.20 21 Pre-
conditioning with subclinical ischaemia or pharmacological
agents including anaesthetics has been shown to provide
cardioprotective effects through diverse signal transduction
pathways.22 PI3K/AKT and MAPK signalling pathways are
known to play an important role in controlling survival and
function of cardiomyocytes and cardiac fibroblasts.23 Antiox-
idants exert cardioprotective effects by decreasing pro-
duction of reactive oxygen species (ROS) during early
reperfusion.24 25
Propofol, a well-known i.v. anaesthetic agent, was reported
to exert significant protective activity against I/R-induced
cardiac injury, partly by reducing the generation of ROS.26 27
Furthermore, propofol was demonstrated to reduce damage
from hydrogen peroxide-induced injury through the PI3K/
AKT signalling pathway in cardiac H9c2 cells,28 and to attenu-
ate angiotensin II-induced cardiomyocyte hypertrophy,18
which is an important process of remodelling after I/R injury.
In the remodelling process, cardiac fibroblasts play the
most prominent role in the development of cardiac fibrosis
after I/R injury and thus, these cells have been considered
as a potential therapeutic target after I/R injury in cardiac
disease. Cardiac fibroblasts constitute more than two-thirds
of the total cells in the normal human heart.29 Pathological
stimuli, such as I/R, inflammation, and induction of TGF-b,
contribute to the increase in collagen type I and III mRNA
expression and MMPs activity including MMP-2 during the
development of cardiac fibrosis.30 Despite the evidence that
cardiac fibroblast activity during remodelling is closely
related to MMPs, which is partly regulated by AKT and ERK
pathways, and propofol could modify the activities of AKT
and ERK pathway, the effect of propofol cardiac fibroblast
function under conditions mimicking I/R injury have not
been investigated.
As the results of the current study indicate, propofol
stimulated AKT and ERK phosphorylation rapidly in rat
cardiac fibroblasts under normoxic condition. U0126, an
ERK inhibitor, decreased propofol-induced AKT activation,
which shows the relationship between AKT and ERK. Propofol
also weakly increased MMP-1, -2, -3, -8, -9, -13, and -14
(MT1-MMP) mRNA expression and enhanced the proteolytic
activities of MMP-2 and -9, whereas TIMP-2 mRNA expression
was decreased compared with cells not exposed to propofol
under normoxic conditions. These propofol-induced changes
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were mitigated by AKT or ERK inhibitors, confirming the role
of AKT and ERK.
Hypoxia is one of the numerous influences on cardiac
matrix remodelling, via ECM turnover and induction of
MMPs and TIMPs. In addition, I/R injury is also a critical
modulator of MMP expression through alternative mechan-
isms.9 The effect of hypoxia was maximal between 1 and 2
h of hypoxic exposure,31 32 and thus serum-starved
fibroblasts were exposed to hypoxia for 1 h followed by
reoxygenation for 24 h in our study. Under these conditions,
propofol increased MMP-1, -9, and -13 mRNA expression, and
attenuated TIMP-1, -2, and -3 mRNA expression more than
seen during normoxia. These changes were more obvious
as the duration of reoxygenation was prolonged. These
results implicate that the influence of propofol on MMP
expression might be amplified during the late period of reox-
ygenation after hypoxia than under normoxic or chronic
hypoxic conditions (data not shown) in these cells.
Subsequently, propofol enhanced cell migration and invasion
of hypoxia-reoxygenated rat cardiac fibroblasts, which was
attenuated by LY204002 or U0126. The results of the
current study are the first to report that propofol influences
the activities of these cells through modulation of MMP and
TIMP expression partly via AKT and ERK pathways, especially
after hypoxia–reoxygenation, which implies a role for propo-
fol as a modulator of matrix regulation.
Angiotensin II, one of the major stimuli of cardiac fibrosis,
increases collagen type I and MMP-2 expression through
induction of oxidative stress.33 Oxidative stress regulates
collagen metabolism and stimulates remodelling of the myo-
cardium in various cell types, such as lung and skin fibroblasts
and endothelial cells. Considering the well-known antioxidant
properties of propofol, increased MMP expression upon
exposure to propofol was unexpected. The observed ability
of propofol to increase migration and invasiveness of cardiac
fibroblasts after hypoxia–reoxygenation in the current study
could adversely affect cardiac remodelling in a clinical
setting. However, diverse and different mechanisms are
involved in regulation of MMP depending on pathological con-
ditions and cell type. In diabetic cardiomyopathy, cardiac
fibrosis has been demonstrated to be associated with
reduced MMP-2 activities and MT1-MMP mRNA expression,
and increased TIMP-2 expression.34 Also, angiotensin II and
glucose-induced reduction of MMPs activity has been
described in diabetic cardiomyopathy.35 Moreover, consider-
ing that proliferation of cardiac fibroblasts play a key role in
cardiac fibrosis and diastolic dysfunction, the finding that pro-
pofol did not affect proliferation seems promising although
the net effect on cardiac fibrosis still needs to be validated.
Different results have been observed regarding cell
proliferation and AKT activation in a previous study addres-
sing the effects of propofol on angiotensin II-induced pro-
liferation of rat cardiac fibroblasts.36 In that study, propofol
was reported to mitigate angiotensin II-induced proliferation
of cardiac fibroblasts partly by activation of the AKT-
endothelial nitric oxide synthase–nitric oxide pathway.
However, in contrast to our study, that study was performed
under normoxic conditions with a known powerful stimulant
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of fibroblast proliferation, angiotensin II and thus it is difficult to
compare the results of the two studies directly. In the absence
of angiotensin II, propofol did not affect cell proliferation per se
in that study, as in our study. Although we did observe signifi-
cant decreases in cell proliferation after exposure to propofol
at high doses, this dose is well above the clinically applied
doses since 30 mM used in this study corresponds to the
usual target blood concentration of 2–4 mg ml21.
Migration is an important cellular function during cell
development and organogenesis including angiogenesis,
and also wound healing and stem or progenitor cell
therapy.10 MT1-MMP promotes granulocyte colony-stimulating
factor-induced haematopoietic stem or progenitor cell mobil-
ization.37 In keratinocytes, MMP-3, -9, and -13 play a crucial
role in skin wound healing in the mouse.38 The role of
MMPs and TIMPs in cell migration and invasion both in vivo
and in vitro has been well documented in various cell
types.39 40 Therefore, the ability of propofol to regulate
MMP and TIMP expression may exert positive effects in
several clinical conditions, such as stem cell therapy for I/
R-induced organ damage, but it is beyond the scope of this
study and merits further evaluation.
In conclusion, propofol affected MMP and TIMP activities
partly through AKT and ERK pathways in normoxic conditions
in rat cardiac fibroblasts and potentiated MMP expression
under conditions of hypoxia–reoxygenation, resulting in
increased cell migration and invasion. These results implicate
propofol as a modulator of matrix regulation.
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